$ICCC
IMMUCELL CORP /DE/ Stock $iccc

$iccc Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000121390024097450 Filed on November 13, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$6.012M
YoY Change		11.4%
Cost Of Revenue		$4.428M
YoY Change		7.23%
Gross Profit		$1.584M
YoY Change		25.0%
Gross Profit Margin		26.34%
Selling, General & Admin		$1.372M
YoY Change		2.99%
% of Gross Profit		86.66%
Research & Development		$786.1K
YoY Change		-29.71%
% of Gross Profit		49.64%
Depreciation & Amortization		$670.3K
YoY Change		-3.64%
% of Gross Profit		42.33%
Operating Expenses		$2.158M
YoY Change		-11.93%
Operating Profit		-$574.9K
YoY Change		-51.45%
Interest Expense		$144.1K
YoY Change		-0.33%
% of Operating Profit
Other Income/Expense, Net		-$125.5K
YoY Change		-151.36%
Pretax Income		-$700.4K
YoY Change		-25.48%
Income Tax		$1.340K
% Of Pretax Income
Net Earnings		-$701.7K
YoY Change		-25.35%
Net Earnings / Revenue		-11.67%
Basic Earnings Per Share		-$0.09
Diluted Earnings Per Share		-$0.09
COMMON SHARES
Basic Shares Outstanding	8.912M shares	7.833M shares
Diluted Shares Outstanding		8.164M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$3.809M
YoY Change		91.39%
Cash & Equivalents		$3.809M
Short-Term Investments
Other Short-Term Assets		$277.2K
YoY Change		-52.22%
Inventory		$7.460M
Prepaid Expenses		$277.1K
Receivables		$2.308M
Other Receivables		$33.34K
Total Short-Term Assets		$13.89M
YoY Change		16.1%
LONG-TERM ASSETS
Property, Plant & Equipment		$25.82M
YoY Change		-8.3%
Goodwill		$95.56K
YoY Change		0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$28.90K
YoY Change		-58.74%
Total Long-Term Assets		$30.56M
YoY Change		-6.2%
TOTAL ASSETS
Total Short-Term Assets		$13.89M
Total Long-Term Assets		$30.56M
Total Assets		$44.45M
YoY Change		-0.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$883.2K
YoY Change		13.23%
Accrued Expenses		$1.726M
YoY Change		85.62%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due		$1.479M
YoY Change		4.9%
Total Short-Term Liabilities		$4.466M
YoY Change		34.19%
LONG-TERM LIABILITIES
Long-Term Debt		$9.423M
YoY Change		-13.55%
Other Long-Term Liabilities		$4.148M
YoY Change		-3.53%
Total Long-Term Liabilities		$13.57M
YoY Change		-10.74%
TOTAL LIABILITIES
Total Short-Term Liabilities		$4.466M
Total Long-Term Liabilities		$13.57M
Total Liabilities		$18.04M
YoY Change		-2.67%
SHAREHOLDERS EQUITY
Retained Earnings		-$14.68M
YoY Change		35.07%
Common Stock		$41.23M
YoY Change		11.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$26.41M
YoY Change
Total Liabilities & Shareholders Equity		$44.45M
YoY Change		-0.22%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$701.7K
YoY Change		-25.35%
Depreciation, Depletion And Amortization		$670.3K
YoY Change		-3.64%
Cash From Operating Activities		-$639.3K
YoY Change		25.36%
INVESTING ACTIVITIES
Capital Expenditures		$88.41K
YoY Change		-78.95%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities		-$88.41K
YoY Change		-83.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		3.212M
YoY Change		104.59%
NET CHANGE
Cash From Operating Activities		-639.3K
Cash From Investing Activities		-88.41K
Cash From Financing Activities		3.212M
Net Change In Cash		2.484M
YoY Change		368.74%
FREE CASH FLOW
Cash From Operating Activities		-$639.3K
Capital Expenditures		$88.41K
Free Cash Flow		-$727.7K
YoY Change		-21.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.12
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.75
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	-1891421	usd
CY2024Q3	iccc	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue	-1068740	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	-1891421	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0348	pure
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.51	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.54	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M12D
	us-gaap	Interest Expense InterestExpense	432529	usd
	us-gaap	Interest Expense InterestExpense	323177	usd
	dei	Entity Registrant Name EntityRegistrantName	IMMUCELL CORP /DE/
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	-1071121	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0348	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.037	pure
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	01-0382980
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	04103
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	-661310	usd
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity File Number EntityFileNumber	001-12934
	dei	Entity Address Address Line1 EntityAddressAddressLine1	56 Evergreen Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Portland
	dei	Entity Address State Or Province EntityAddressStateOrProvince	ME
	dei	City Area Code CityAreaCode	(207)
	dei	Local Phone Number LocalPhoneNumber	878-2770
	dei	Security12b Title Security12bTitle	Common Stock, $0.10 par value per share
	dei	Trading Symbol TradingSymbol	ICCC
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8911589	shares
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3808633	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	978741	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2307913	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2185383	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	7460452	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	7811841	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	310488	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	493885	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	13887486	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	11469850	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25820333	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27575683	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4592718	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4571149	usd
CY2024Q3	us-gaap	Goodwill Goodwill	95557	usd
CY2023Q4	us-gaap	Goodwill Goodwill	95557	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	23880	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	38208	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	28899	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	57655	usd
CY2024Q3	us-gaap	Assets Assets	44448873	usd
CY2023Q4	us-gaap	Assets Assets	43808102	usd
CY2024Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1479058	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1428807	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	482244	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	644276	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2504535	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2124337	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4465837	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4197420	usd
CY2024Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	9422961	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	10540496	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4148404	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4077109	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	13571365	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	14617605	usd
CY2024Q3	us-gaap	Liabilities Liabilities	18037202	usd
CY2023Q4	us-gaap	Liabilities Liabilities	18815025	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.1
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.1
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8896398	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7814165	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8833097	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7750864	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	889641	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	781417	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	40338793	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	36357239	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14678281	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12007097	usd
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	63301	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	63301	shares
CY2024Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	138482	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	138482	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	26411671	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	24993077	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44448873	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43808102	usd
CY2024Q3	us-gaap	Revenues Revenues	6011573	usd
CY2023Q3	us-gaap	Revenues Revenues	5396500	usd
	us-gaap	Revenues Revenues	18742040	usd
	us-gaap	Revenues Revenues	12375708	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4428019	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4129619	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13632642	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9764164	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	1583554	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	1266881	usd
	us-gaap	Gross Profit GrossProfit	5109398	usd
	us-gaap	Gross Profit GrossProfit	2611544	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	786136	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1118489	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3079189	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3328397	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	844045	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	817486	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2629925	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2416701	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	528267	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	514952	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1661838	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1611026	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	2158448	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2450927	usd
	us-gaap	Operating Expenses OperatingExpenses	7370952	usd
	us-gaap	Operating Expenses OperatingExpenses	7356124	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-574894	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1184046	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2261554	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4744580	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-125456	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	244275	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-405610	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	113092	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-700350	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-939771	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2667164	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4631488	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1340	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	229	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4020	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3279	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-701690	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-940000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2671184	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4634767	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8164423	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7746864	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7908425	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7746864	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.6
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8164423	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7746864	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7908425	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7746864	shares
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.6
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	23455463	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-701690	usd
CY2024Q3	iccc	Offering Costs On Follow Up Offering Of Common Stock OfferingCostsOnFollowUpOfferingOfCommonStock	110838	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3580341	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	77557	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	26411671	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	26857055	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-940000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	96434	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	26013489	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	24993077	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2671184	usd
	iccc	Offering Costs On Follow Up Offering Of Common Stock OfferingCostsOnFollowUpOfferingOfCommonStock	275640	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3833090	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	256688	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	26411671	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	30380049	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4634767	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	268207	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	26013489	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2671184	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4634767	usd
	us-gaap	Depreciation Depreciation	1999005	usd
	us-gaap	Depreciation Depreciation	2027788	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14328	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14328	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	31859	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	12525	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	256688	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	268207	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-14557	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8099	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	112306	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-95881	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	122530	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	105985	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-351389	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1347124	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-183397	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	201211	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-28756	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-6587	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	386995	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-95493	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	360954	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3951165	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	269509	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1811169	usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	115127	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4500	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2474	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-265009	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1923822	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	3000000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3833090	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	2000000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	2000000	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	1094106	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	829015	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	5037	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	98098	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2733947	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2072887	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2829892	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3802100	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	978741	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5791562	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3808633	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1989462	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	5905	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	7205	usd
	us-gaap	Interest Paid Net InterestPaidNet	404077	usd
	us-gaap	Interest Paid Net InterestPaidNet	303752	usd
	iccc	Change In Capital Expenditures Included In Accounts Payable And Accrued Expenses ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses	6797	usd
	iccc	Change In Capital Expenditures Included In Accounts Payable And Accrued Expenses ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses	56441	usd
	iccc	Decrease Increase In Operating Lease Rightofuse Asset And Operating Lease Liability DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability	103115	usd
	iccc	Decrease Increase In Operating Lease Rightofuse Asset And Operating Lease Liability DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability	2090298	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BUSINESS OPERATIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">ImmuCell Corporation (the “Company”, “we”, “us”, “our”) was originally incorporated in Maine in 1982 and reincorporated in Delaware in 1987, in conjunction with an initial public offering of common stock. We are an animal health company whose purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. We focus on the two most critical stages of dairy productivity, those being the first 30 days of life and the first 30 days of lactation. Our concentrated colostrum and purified Nisin technologies offer unique animal health solutions during these periods when immunity is at its most vulnerable. As disclosed in Note 17, “Segment Information”, one of our business segments is dedicated to Scours and the other is focused on Mastitis. We manufacture and market the <b>First Defense<sup>®</sup></b> product line, providing <b>Immediate Immunity™</b> to prevent scours in newborn dairy and beef calves. We have expanded this line into four different products with formulations targeting <i>E. coli</i>, coronavirus and rotavirus pathogens. We are also in the late stages of developing <b>Re-Tain<sup>®</sup></b>, a treatment for lactating dairy cows with subclinical mastitis. Mastitis is the most significant cause of economic loss to the dairy industry. These products help reduce the need to use traditional antibiotics in food producing animals. We are subject to certain risks including dependence on key individuals and third-party providers of critical goods and services, competition from other larger companies, the successful sale of existing products and the development of new viable products with appropriate regulatory approvals, where applicable. A combination of the conditions, trends and concerns related to or arising from inflation, rising interest rates and potential recessionary conditions in the United States and/or internationally, could have a corresponding negative effect on our business and operations. We are experiencing price increases in key components, supportive services, transportation and other supplies that are causing our costs of goods sold to increase. We have experienced contamination events from time to time in our production process, beginning in the third quarter of 2022, as disclosed previously. We implemented a production slowdown during 2023 to remediate this problem, which led to the recognition of lower sales and gross margin. The last identified contamination event occurred during the first half of April of 2024, and we have been operating without further contamination events since then and through the date of this filing.</p>
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Salvage Value Percentage PropertyPlantAndEquipmentSalvageValuePercentage	0.86	pure
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(j) Concentration of Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Three-Month <br/> Periods Ended September 30,</b></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Nine-Month<br/> Periods Ended September 30,</b></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">43</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">50</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">44</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Company B</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Trade accounts receivable due from significant customers that amounted to 10% or more of our total trade accounts receivable are detailed in the following table:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>As of <br/> September 30, 2024</b></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>As of <br/> December 31, 2023</b></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right">37</td> <td style="width: 1%; text-align: left">%</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right">43</td> <td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Company B</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">34</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">36</td> <td style="text-align: left">%</td></tr> </table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p>
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	77557	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	96434	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	256688	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	268207	usd
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	661000	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	616500	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	661000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	616500	shares
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-701690	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-940000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2671184	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4634767	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8164423	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7746864	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7908425	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7746864	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8164423	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7746864	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7908425	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7746864	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.6
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.6
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(p) Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The <span style="font-family: Times New Roman, Times, Serif">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ from those estimates and are subject to change in the near term. Changes in estimates are recorded during the period in which they become known. Significant estimates include our valuation of inventory, deferred tax assets and costs of goods sold</span>.</p>
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3808633	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	978741	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2307913	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2185383	usd
CY2024Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	1313766	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1594028	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	6124394	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	5815194	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	22292	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	402619	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	7460452	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	7811841	usd
	us-gaap	Inventory Write Down InventoryWriteDown	368723	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	527133	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	277146	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	454152	usd
CY2024Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	33342	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	39733	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	310488	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	493885	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	46201529	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	46059631	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20381196	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	18483948	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25820333	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27575683	usd
CY2024Q3	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	49652	usd
CY2023Q3	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	43503	usd
	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	120814	usd
	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	100142	usd
CY2024Q3	us-gaap	Depreciation Depreciation	670346	usd
CY2023Q3	us-gaap	Depreciation Depreciation	695635	usd
	us-gaap	Depreciation Depreciation	1999005	usd
	us-gaap	Depreciation Depreciation	2027788	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	191040	usd
CY2024Q3	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4776	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4776	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14328	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14328	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	23880	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	38208	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	191040	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	167160	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	23880	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	191040	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	152832	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	38208	usd
CY2024Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	876836	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	874558	usd
CY2024Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	6378	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	13175	usd
CY2024Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1142318	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	942999	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	101725	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	97800	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	376112	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	192754	usd
CY2024Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1166	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3051	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2504535	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2124337	usd
CY2022Q1	us-gaap	Participating Mortgage Loans Unamortized Debt Discount Amount ParticipatingMortgageLoansUnamortizedDebtDiscountAmount	2000000	usd
CY2022Q1	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.0358	pure
CY2024Q3	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.0353	pure
CY2020Q1	us-gaap	Line Of Credit LineOfCredit	1000000	usd
CY2024Q3	us-gaap	Deferred Finance Costs Current Gross DeferredFinanceCostsCurrentGross	173305	usd
	us-gaap	Interest Costs Incurred InterestCostsIncurred	5037	usd
	us-gaap	Interest Costs Incurred InterestCostsIncurred	0	usd
CY2024Q3	us-gaap	Line Of Credit LineOfCredit	1000000	usd
CY2024Q3	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	368249	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	3000000	usd
CY2023Q3	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	325737	usd
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	1094106	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	3000000	usd
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	829015	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	3000000	usd
CY2023	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	1185774	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	2000000	usd
CY2022	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	897125	usd
CY2024Q3	iccc	Debt Issuance Costs2024 DebtIssuanceCosts2024	5583	usd
CY2024Q3	iccc	Debt Issuance Costs2025 DebtIssuanceCosts2025	21314	usd
CY2024Q3	iccc	Debt Issuance Costs2026 DebtIssuanceCosts2026	13580	usd
CY2024Q3	iccc	Debt Issuance Costs2027 DebtIssuanceCosts2027	5420	usd
CY2024Q3	iccc	Debt Issuance Costs2028 DebtIssuanceCosts2028	3513	usd
CY2024Q3	iccc	Debt Issuance Costshereafter DebtIssuanceCostshereafter	11347	usd
CY2024Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	60757	usd
CY2024Q3	iccc	Debt Discount Cost DebtDiscountCost	5223	usd
CY2024Q3	iccc	Debt Discount Cost2025 DebtDiscountCost2025	20891	usd
CY2024Q3	iccc	Debt Discount Cost2026 DebtDiscountCost2026	11344	usd
CY2024Q3	iccc	Debt Discount Cost Total DebtDiscountCostTotal	37458	usd
CY2024Q3	iccc	Long Term Debt2024 LongTermDebt2024	363418	usd
CY2024Q3	iccc	Long Term Debt2025 LongTermDebt2025	1497626	usd
CY2024Q3	iccc	Long Term Debt2026 LongTermDebt2026	3316349	usd
CY2024Q3	iccc	Long Term Debt2027 LongTermDebt2027	793406	usd
CY2024Q3	iccc	Long Term Debt Total2028 LongTermDebtTotal2028	344110	usd
CY2024Q3	iccc	Long Term Debt Thereafter LongTermDebtThereafter	4587110	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10902019	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	222379	usd
CY2024Q3	us-gaap	Other Deferred Compensation Arrangements Liability Current OtherDeferredCompensationArrangementsLiabilityCurrent	300000	usd
CY2023Q1	us-gaap	Other Deferred Compensation Arrangements Liability Current OtherDeferredCompensationArrangementsLiabilityCurrent	100000	usd
CY2024Q1	us-gaap	Other Deferred Compensation Arrangements Liability Current OtherDeferredCompensationArrangementsLiabilityCurrent	100000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	275000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	200000	usd
CY2024Q3	iccc	Capital Expenditures Committed CapitalExpendituresCommitted	186000	usd
	iccc	Purchaseof Inventory PurchaseofInventory	1818000	usd
CY2024Q3	iccc	Commitments Related To Information Technology Services And Other Obligations CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations	711000	usd
CY2019Q3	us-gaap	Area Of Land AreaOfLand	14300	sqft
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	106880	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	98714	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	320639	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	244954	usd
CY2024Q3	us-gaap	Variable Lease Cost VariableLeaseCost	21486	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	9720	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	50638	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	27054	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	128366	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	108434	usd
	us-gaap	Lease Cost LeaseCost	371277	usd
	us-gaap	Lease Cost LeaseCost	272008	usd
CY2024Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	144315	usd
CY2023Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	69742	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	432945	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	131476	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P18Y3M18D
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P19Y3M18D
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P18Y3M18D
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P19Y3M18D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.066	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.063	pure
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.066	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.063	pure
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	144315	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	711623	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	349744	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	356732	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	363870	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	5949488	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7875772	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3245124	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	4630648	usd
CY2016Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1123810	shares
CY2016Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.25
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5900003	usd
CY2016Q1	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	5313224	usd
CY2017Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	200000	shares
CY2017Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.25
CY2017Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1050000	usd
CY2017Q3	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	1034164	usd
CY2017Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	417807	shares
CY2017Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	7.3
CY2017Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3049991	usd
CY2017Q4	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	2734173	usd
CY2019Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1636364	shares
CY2019Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.5
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9000002	usd
CY2019Q1	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	8303436	usd
CY2021Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	515156	shares
CY2021Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	8.25
CY2021Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4250038	usd
CY2021Q2	iccc	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	4233026	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	11000000	shares
CY2024Q2	iccc	Fees Initially Capitalized And Later Offset FeesInitiallyCapitalizedAndLaterOffset	152272	usd
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1082233	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.19
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.16
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.69
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.82
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.8
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.49
CY2024Q3	iccc	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested	6.97
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.49
CY2024Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	73000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	108000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.19
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	433317	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.52	pure
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y1M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y3M18D
	us-gaap	Employee Stock Ownership Plan Esop Weighted Average Purchase Price Of Shares Purchased EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased	70
	iccc	Exercisable And Transferable Description ExercisableAndTransferableDescription	The Rights (as amended) become exercisable and transferable apart from the common stock upon the earlier of i) 10 days following a public announcement that a person or group (Acquiring Person) has, without the prior consent of the Continuing Directors (as such term is defined in the Rights Agreement), acquired beneficial ownership of 20% or more of the outstanding common stock or ii) 10 days following commencement of a tender offer or exchange offer the consummation of which would result in ownership by a person or group of 20% or more of the outstanding common stock (the earlier of such dates being called the Distribution Date).
	us-gaap	Investment Company Purchase Premium Per Share InvestmentCompanyPurchasePremiumPerShare	70
	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Change Due To Subsequent Interim Measurement Weighted Average Expected Long Term Rate Of Return On Plan Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets	0.50	pure
	iccc	Right To Acquire Per Share RightToAcquirePerShare	0.005
	us-gaap	Employee Stock Ownership Plan Esop Plan Description EmployeeStockOwnershipPlanESOPPlanDescription	Our Board of Directors decided to seek an advisory vote by stockholders at the Annual Meeting of Stockholders held in June of 2022, as to whether to extend the Rights Plan by one year to September 19, 2023. Of the votes actually cast on this proposal, 65% voted in favor, 32% voted against and 3% abstained. On the basis of this vote, our Board of Directors voted to extend the Rights Plan by one year to September 19, 2023. Our Board of Directors decided to seek another advisory vote by stockholders at the Annual Meeting of Stockholders held in June of 2023, as to whether to extend the Rights Plan by another year to September 19, 2024. Of the votes actually cast on this proposal, 65.10% voted in favor, 34.60% voted against and 0.30% abstained. On the basis of this vote, our Board of Directors voted to extend the Rights Plan by one year to September 19, 2024. Recognizing that there might be a substantial number of broker non-votes, our Board of Directors disclosed that it would be guided by the votes actually cast on these proposals in deciding whether to extend the expiration date of such plan by one year.
CY2024Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6011573	usd
CY2024Q3	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5396500	usd
CY2023Q3	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	18742040	usd
	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	12375708	usd
	iccc	Revenue Sales Obligation Percentage RevenueSalesObligationPercentage	1	pure
CY2024Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6011573	usd
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	1	pure
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5396500	usd
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	1	pure
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	18742040	usd
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	1	pure
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	12375708	usd
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	1	pure
CY2024Q3	us-gaap	Interest Expense InterestExpense	144141	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	144616	usd
CY2023Q3	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	68	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-14557	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-8099	usd
CY2024Q3	us-gaap	Interest Income Other InterestIncomeOther	18685	usd
CY2023Q3	us-gaap	Interest Income Other InterestIncomeOther	23696	usd
	us-gaap	Interest Income Other InterestIncomeOther	41476	usd
	us-gaap	Interest Income Other InterestIncomeOther	79134	usd
CY2023Q3	us-gaap	Insurance Recoveries InsuranceRecoveries	365127	usd
	us-gaap	Insurance Recoveries InsuranceRecoveries	365127	usd
	us-gaap	Other Income OtherIncome	107	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-125456	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	244275	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-405610	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	113092	usd
CY2024Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	10805	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	8687	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	31859	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	12525	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1340	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	229	usd
CY2024Q3	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.01	pure
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4020	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3279	usd
	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.01	pure
	us-gaap	Other Noncash Income Tax Expense OtherNoncashIncomeTaxExpense	563252	usd
CY2024Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2024Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6011573	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4428019	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	1583554	usd
CY2024Q3	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	786136	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	844045	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	528267	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	2158448	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-574894	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5396500	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4129619	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	1266881	usd
CY2023Q3	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	1118489	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	817486	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	514952	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2450927	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1184046	usd
CY2024Q3	us-gaap	Assets Assets	44448873	usd
CY2023Q3	us-gaap	Assets Assets	44545022	usd
CY2024Q3	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	685927	usd
CY2023Q3	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	709098	usd
CY2024Q3	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	88412	usd
CY2023Q3	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	420515	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	18742040	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13632642	usd
	us-gaap	Gross Profit GrossProfit	5109398	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	3079189	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2629925	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1661838	usd
	us-gaap	Operating Expenses OperatingExpenses	7370952	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2261554	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	12375708	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9764164	usd
	us-gaap	Gross Profit GrossProfit	2611544	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	3328397	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2416701	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1611026	usd
	us-gaap	Operating Expenses OperatingExpenses	7356124	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4744580	usd
CY2024Q3	us-gaap	Assets Assets	44448873	usd
CY2023Q3	us-gaap	Assets Assets	44545022	usd
	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	2045192	usd
	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	2054641	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	269509	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1811169	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	17471669	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13602385	usd
CY2023	us-gaap	Gross Profit GrossProfit	3869284	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	4394852	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3088215	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2134295	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	9617362	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-5748078	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	18567962	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10919183	usd
CY2022	us-gaap	Gross Profit GrossProfit	7648779	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	4493872	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3190033	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2263817	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	9947722	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2298943	usd
CY2023Q4	us-gaap	Assets Assets	43808102	usd
CY2022Q4	us-gaap	Assets Assets	44860649	usd
CY2023	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	2739620	usd
CY2022	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	2495241	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1892513	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3975274	usd
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	390322	usd
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	128521	usd
	iccc	Employees Salary Percentage EmployeesSalaryPercentage	1	pure
	iccc	Employees Salary Contribution Percentage EmployeesSalaryContributionPercentage	0.50	pure
CY2024Q3	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	55989	usd
CY2023Q3	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	50126	usd
	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	159504	usd
	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	135698	usd
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets		usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse		usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse		usd
CY2024Q3	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
CY2024Q3	iccc	Debt Discount Cost2027 DebtDiscountCost2027		usd
CY2024Q3	iccc	Debt Discount Cost2028 DebtDiscountCost2028		usd
CY2024Q3	iccc	Debt Discount Cost Thereafter DebtDiscountCostThereafter		usd
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate		pure
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q3	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
CY2024Q3	us-gaap	Insurance Recoveries InsuranceRecoveries		usd
	us-gaap	Insurance Recoveries InsuranceRecoveries		usd
CY2024Q3	us-gaap	Other Income OtherIncome		usd
CY2023Q3	us-gaap	Other Income OtherIncome		usd
	us-gaap	Other Income OtherIncome		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Central Index Key EntityCentralIndexKey	0000811641

Files In Submission

Name	View Source	Status
0001213900-24-097450-index-headers.html	Edgar Link	pending
0001213900-24-097450-index.html	Edgar Link	pending
0001213900-24-097450.txt	Edgar Link	pending
0001213900-24-097450-xbrl.zip	Edgar Link	pending
ea0220527-10q_immucell.htm	Edgar Link	pending
ea022052701ex31_immucell.htm	Edgar Link	pending
ea022052701ex32_immucell.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
iccc-20240930.xsd	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
iccc-20240930_def.xml	Edgar Link	unprocessable
iccc-20240930_lab.xml	Edgar Link	unprocessable
iccc-20240930_pre.xml	Edgar Link	unprocessable
ea0220527-10q_immucell_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
iccc-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ICCC
IMMUCELL CORP /DE/ Stock $iccc

2024 Q4 Form 10-Q Financial Statement

#000121390024097450 Filed on November 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICCC IMMUCELL CORP /DE/ Stock $iccc

2024 Q4 Form 10-Q Financial Statement

#000121390024097450 Filed on November 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICCC
IMMUCELL CORP /DE/ Stock $iccc